Ignite Creation Date:
2025-12-24 @ 11:42 PM
Ignite Modification Date:
2025-12-25 @ 9:33 PM
Study NCT ID:
NCT01274351
Status:
COMPLETED
Last Update Posted:
2020-09-01
First Post:
2011-01-04
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-01-25
Start Date Type:
ACTUAL
Primary Completion Date:
2019-08-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-08-01
Completion Date Type:
ACTUAL
First Submit Date:
2011-01-04
First Submit QC Date:
None
Study First Post Date:
2011-01-11
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-07-30
Results First Submit QC Date:
None
Results First Post Date:
2020-09-01
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-08-18
Last Update Post Date:
2020-09-01
Last Update Post Date Type:
ACTUAL